Whitepapers

This ebook discusses how bioreactors and their components can be employed in cell culture with the goal of increasing process reproducibility.

Traditionally, producing biotherapeutics such as monoclonal antibodies required a multi-step process to remove impurities, including host-cell proteins, DNA, adventitious viruses, and antibody aggregates. However, by converting the process from batch chromatography to multi-column chromatography (MCC), there is potential to reduce costs and shorten production times for the capture and purification of high-quality mAbs.

Transitioning to intensified, continuous chromatography can increase efficiencies and decrease time and cost when analyzing protein A.

Gain access to essential strategies and solutions for optimizing your CHO cell culture workflow. This exclusive resource offers valuable insights and practical guidance tailored to the challenges of scaling up monoclonal antibody manufacturing with CHO cells.

This asset outlines the comprehensive support and guidance offered by the FAS team for optimizing monoclonal antibody (mAb) manufacturing processes using the Efficient-Pro medium and feeds. Readers will learn about the tailored assistance provided at every stage, including troubleshooting, recommendations, ongoing support, site visits, and prioritization of confidentiality.

Learn about how Efficient-Pro Medium and Feeds elevate productivity in CHO-K1, CHO-S, and DG44 cells for bioproduction in this comprehensive content piece.

Discover how the Gibco™ Efficient-Pro™ system boosts productivity, enhances cell viability, and ensures superior product quality with minimal impurities. Packed with detailed fed-batch study results, this guide offers actionable insights and practical tips to optimize your bioproduction processes, ensuring you achieve higher yields and consistent, high-quality outcomes. Dive into this indispensable asset to elevate your manufacturing workflow to the next level.

In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.

Download the white paper and learn how Implementing Real-Time Control of Carbon Dioxide can Impact Productivity at R&D and Production Scale Bioreactors. Dissolved CO₂ is a Critical Process Parameter (CPP) in biopharma production processes, as it has a direct impact on product titer and its critical quality attributes. It influences other culture parameters like extracellular and intracellular pH, as well as key performance indicators such as Viable Cell Density. Uncontrolled dissolved carbon dioxide levels in the bioreactor can result in growth inhibition, lower product titer, and decreased product quality.

How does PAT apply to the bioreactor? Download our comprehensive white paper and explore what PAT means in Biopharma Upstream processes. Discover cutting-edge solutions to effectively monitor critical process parameters and ensure product quality.

mRNA vaccines and therapeutics continue to reshape medicine, providing unique opportunities to prevent and treat a wide range of diseases. In order to unleash the full potential of mRNA, however, one must consider various factors.

Bio-Rad Laboratories, Inc., Pioneer™ Antibody Discovery Platform helps streamline the phage display-based discovery process and provides researchers with superior identification of high-quality therapeutic antibodies.

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research.

As today’s labs continue to evolve, the software solutions that support them must too. Likewise, laboratory and organization leadership must be open to the advancements available to them from modern technologies. In this white paper, learn how a SaaS-based LIMS modernization program optimizes data management, fosters collaboration, and improves decision-making to stay at the forefront of scientific innovation.

Innovation is the engine that powers a company’s growth and product development, and for enterprises with R&D laboratories, those lab environments are the greatest source of this innovation. In this white paper, learn how a platform approach to scientific data management, including semantic search, advanced analytics, and lab automation, leads to better enterprise decisions at the executive level, optimized lab performance, more discoveries, and stronger product pipelines.

Biopharmaceutical companies are increasingly partnering with CDMOs equipped with technologies and expertise to support analytical testing during process development. The level of complexity required to develop and manufacture cell and gene therapies has increased, including the use of various raw materials, custom reagents, and tailored approaches for managing complex diseases.

Charge heterogeneity is present in most biopharmaceutical protein products. During the manufacturing process, charge heterogeneity of the protein therapeutics can occur due to enzymatic cleavage and chemical post-translational modifications (PTM). For therapeutics like ADCs, not only the antibody contributes to the heterogeneity but also the linker and payload, which add even more complexity to the charge variant profiles. Characterizing the charge heterogeneity of ADCs is essential for critical quality attribute (CQA) assessment to ensure drug safety, efficacy, and potency.

Experience flexibility with TaqMan assays, offering over 2.8 million predesigned options to meet your specific needs.

An intelligent, on-premise platform connecting all the steps of your post-discovery routine qPCR workflows into one single ecosystem. Contact sales for a demo

Innovative qPCR tools for your bioanalysis and quality control. Fast-track your bioanalysis & QC with scalable innovative qPCR tools.

TaqMan SNP Genotyping Assays help you detect and distinguish single-nucleotide polymorphisms (SNPs) accurately and efficiently.

Multiplex better with the newest additions to the TaqMan portfolio

Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.

Discover how to accurately analyze purity and impurities, determine sequences, and more with next-generation technologies from Agilent.